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A new strategy based on lentiviral-mediated delivery of mutant
huntingtin (htt) was used to create a genetic model of Hunting-
ton’s disease (HD) in rats and to assess the relative contribution
of polyglutamine (CAG) repeat size, htt expression levels, and
protein length on the onset and specificity of the pathology.
Lentiviral vectors coding for the first 171, 853, and 1520 amino
acids of wild-type (19 CAG) or mutant htt (44, 66, and 82 CAG)
driven by either the phosphoglycerate kinase 1 (PGK) or the
cytomegalovirus (CMV) promoters were injected in rat striatum.
A progressive pathology characterized by sequential appear-
ance of ubiquitinated htt aggregates, loss of dopamine- and
cAMP-regulated phosphoprotein of 32 kDa staining, and cell
death was observed over 6 months with mutant htt. Earlier
onset and more severe pathology occurred with shorter frag-
ments, longer CAG repeats, and higher expression levels. In-
terestingly, the aggregates were predominantly located in the
nucleus of PGK-htt171-injected rats, whereas they were
present in both the nucleus and processes of CMV-htt171-
injected animals expressing lower transgene levels. Finally, a
selective sparing of interneurons was observed in animals in-
jected with vectors expressing mutant htt. These data demon-
strate that lentiviral-mediated expression of mutant htt provides
a robust in vivo genetic model for selective neural degeneration
that will facilitate future studies on the pathogenesis of cell
death and experimental therapeutics for HD.
Key words: Huntington’s disease; genetic model; huntingtin;
lentiviral vector; gene delivery; rat
Huntington’s disease (HD) is caused by the expansion of a CAG
trinucleotide within the coding region of the huntingtin (htt) gene
(Huntington’s Disease Collaborative Research Group, 1993).
The hallmark features of HD are cognitive impairment, psychi-
atric disturbances, and motor disability irreversibly progressing to
death 10–20 years after the onset of the symptoms (Vonsattel and
DiFiglia, 1998). Despite the widespread expression of htt, the first
affected region is the striatum, and, at a later stage of the disease,
other brain areas such as the cerebral cortex are affected.
To gain insight into the molecular steps mediating neurotoxic-
ity, genetic models of HD have been developed. Genomic DNA
or cDNAs coding for truncated or full-length mutant huntingtin
proteins under the control of endogenous or heterologous pro-
moters have been used to produce transgenic or knock-in mice
(Mangiarini et al., 1996; White et al., 1997; Reddy et al., 1998;
Hodgson et al., 1999; Schilling et al., 1999; Shelbourne et al., 1999;
Wheeler et al., 1999; Yamamoto et al., 2000; Lin et al., 2001). The
severity of the pathology varies among these animals, but neuro-
logical phenotypes reminiscent of early HD, including tremor,
seizure, motor deficits, decreased brain weight, alterations of
neurotransmitter receptor levels, nuclear inclusions, and astro-
gliosis were reported. Interestingly, reproducible and substantial
loss of spiny medium neurons were not observed, even in trans-
genic mice expressing full-length htt (Hodgson et al., 1999; Reddy
et al., 1999a). Moreover, side effects attributable to the wide-
spread overexpression of htt and premature death not associated
with the striatal pathology were reported (Mangiarini et al., 1996;
Hurlbert et al., 1999; Reddy et al., 1999a,b).
We have therefore investigated whether lentiviral-mediated
delivery of mutant htt can be used to address some of these issues
and to create a genetic model of HD in rats. The potential use of
viral-based gene transfer to generate animal models has been
established by Senut et al. (2000) with an adeno-associated vector
expressing expanded CAG repeats fused to the green fluorescent
protein. Poly(Q)-dependent degeneration was observed in the
striatum of rats, but the specificity of the pathology was not
evaluated. Importantly, viral-mediated delivery of mutant htt has
not been used to develop animal models of HD. In this context,
lentiviral vectors are particularly suitable because of their large
cloning capacity and high transduction efficiency. Previous studies
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have demonstrated that vesicular stomatitis virus G-protein-
pseudotyped lentiviral vectors have a strong neurotropism and
lead to long-term and robust transgene expression (Naldini et al.,
1996; Blo¨mer et al., 1997; Naldini, 1998; de Almeida et al., 2001).
The present strategy holds various advantages over transgenic
mice. Genetic models based on multiple variations of the trans-
gene being expressed can be created in a short period. High
transgene expression levels can be reached with lentiviral vectors,
an important feature to exacerbate the disease process and to
induce neuronal degeneration but avoiding side effects associated
with a widespread overexpression of mutant huntingtin (Naldini
et al., 1996; De´glon et al., 2000; Kordower et al., 2000). Regulated
expression systems allowing gene-dosing experiments are avail-
able (Kafri et al., 2000). The specificity of the neuropathology can
be assessed by targeting well defined brain regions. Finally, mod-
els can be established in different mammalian species, thereby
providing an opportunity to conduct studies in nonhuman
primates.
We have therefore cloned the cDNAs coding for the first 171,
853, and 1520 amino acids of huntingtin protein with 19 (wild
type), 44, 66, and 82 CAG repeats (mutant) in transfer vectors
with cytomegalovirus (CMV) or mouse phosphoglycerate kinase
1 (PGK) internal promoters. The viruses expressing wild-type or
mutant huntingtin were injected in the right and left striata of
adult Wistar rats, respectively. A time course study was per-
formed over 24 weeks to measure the appearance of nuclear
inclusions, loss of neuronal markers, and subsequent cell death of
GABAergic neurons as well as the susceptibility of choline acetyl-
transferase (ChAT) and NADPH diaphorase (NADPH-d) inter-
neurons after lentiviral injection.
MATERIALS AND METHODS
Lentiviral vector production
Human huntingtin cDNAs coding for the first 171, 583, and 1520 amino
acids of the protein with 19, 44, 66, or 82 CAG repeats (Cooper et al.,
1998; Schilling et al., 2001) were cloned in self-inactivating transfer
vector (SIN) containing the woodchuck hepatitis virus postregulatory
element (W) (De´glon et al., 2000). Mouse PGK and CMV were used as
internal promoters. The viral particles were produced by transient cal-
cium phosphate transfection of 3  10 6 human embryonic kidney 293T
cells (Ory et al., 1996) plated in 10 cm Petri dishes (Falcon; Becton
Dickinson, Rutherford, NJ) with 13 g of pCMVDR-8.92 packaging
construct, 3.75 g of pMD.G, 3 g of pRSV-Rev, and 13 g of SIN-W-
PGK or SIN-W-CMV transfer vectors, as previously described (Hot-
tinger et al., 2000). Forty-eight hours later, the supernatants were col-
lected, filtered, and concentrated by ultracentrifugation, and the particle
content was determined by p24 antigen ELISA (PerkinElmer Life Sci-
ences, Boston, MA). For the in vivo experiments, the different batches of
viruses were matched for particle content and used at 200,000 ng of
p24/ml.
Western blot analysis
293T cells were plated in six-well tissue culture dishes (Becton Dickin-
son) at a density of 150,000 cells per well. The cells were infected with the
lentiviral vectors matched for particle content (600 ng of p24 antigen/
well). Twelve hours later, the medium was removed and replaced with
fresh DMEM containing 10% fetal calf serum, 2 mM L-glutamine, 4.5
gm/l glucose, 100 U/ml penicillin, and 100 U/ml streptomycin. Three
days after infection, the cells were washed in 0.05 M PBS, harvested, and
lysed in 0.05 M KHPO4, pH 7.8, and 0.03% Triton X-100 (Sigma, St.
Louis, MO), with a mixture of protease inhibitors (pronase, thermolysin,
chymotrypsin, trypsin, and papain; Roche Pharma, Reinach, Switzer-
land). The cell lysates were centrifuged at 4°C for 30 min at 10,000  g.
Protein concentration was determined with the bicinchoninic acid assay
(Pierce, Rockford, IL). Sixty micrograms of the protein extracts were
analyzed on 7.5 or 10% SDS-polyacrylamide gels. The proteins were
transferred to nitrocellulose membranes (Bio-Rad, Hercules, CA) using
a buffer of 192 mM Tris-HCl, 25 mM glycine, and 10% methanol. The
blots were blocked in 10% normal goat serum (NGS; Dako, Glostrup,
Denmark) in PBS for 2 hr at room temperature (RT), followed by
incubation for 48 hr with a 1:4000 dilution of the EM48 anti-huntingtin
antibody (kindly provided by Dr. X. J. Li, Emory University School of
Medicine, Atlanta, GA; Li et al., 1999). Blots were washed for 2 hr and
incubated with a biotinylated goat anti-rabbit antibody (1:4000; Vector
Laboratories, Burlingame, CA) for 1.5 hr at RT. After a 1 hr wash, the
blot was incubated with avidin–peroxidase reagent [Vectastain avidin–
biotin complex (ABC) kit; Vector Laboratories] for 30 min at RT. The
detection was performed using an Enhanced Chemiluminescence Plus
kit (Amersham Biosciences, Uppsala, Sweden).
Animals
Adult female Wistar rats (Iffa-Credo) weighing 200 gm were used. The
animals were housed in a controlled temperature room that was main-
tained on a 12 hr light /dark cycle. Food and water were available ad
libitum. The experiments were performed out in accordance with the
European Community Council directive 86/609/EEC for care and use of
laboratory animals.
Injection of the lentiviruses
The stereotaxic injections (David Kopf Instruments, Tujunga, CA; n 
3 per group) were performed under pentobarbital anesthesia (45 mg/kg,
i.p.) using a syringe (Hamilton, Reno, NV) with a 30 gauge blunt-tip
needle. Lentiviral vectors expressing the wild-type or mutant htt were
injected in the left or the right striatum, respectively. The animal re-
ceived two 4 l injections of lentiviral vectors in each side at the
following coordinates: 1.0 and 0.0 rostral to bregma, 3.0 and 3.3 lateral to
midline, and 5.0 ventral from the skull surface, with the mouth bar set at
3.3. The viruses were injected at 0.2 l /min by means of an automatic
injector (Stoelting Co.), and the needle was left in place for 5 min. The
skin was closed using a 6-0 Vicryl suture (Ethicon; Johnson & Johnson,
Brussels, Belgium). Three animals were killed, and the brains processed
for immunohistochemistry 1, 2, 4, 8, and 12 weeks after injection. A
long-term study was performed with lentivirus coding for htt171, htt853,
and htt1520 (n  3 per group). In these animals, a single 4 l dose of
lentivirus was injected 0.5 rostral to bregma, 3.0 lateral to midline, and
5.0 ventral from the skull surface, with the mouth bar set at 3.3.
Histological processing
Tissue preparation. At the time of killing, the animals were anesthetized
with a sodium pentobarbital overdose, transcardially perfused, post-fixed
in 4% paraformaldehyde for 24 hr, and finally cryoprotected in 25%
sucrose and 0.1 M phosphate buffer for 48–72 hr. The brains were frozen
in dry ice, and coronal sections were cut on a sliding microtome cryostat
(Cryocut 1800; Leica Microsystems, Nussloch, Germany) at a tempera-
ture of 20°C and a thickness of 25 m. Free-floating sections through-
out the entire striatum were collected in PBS containing 0.12 M sodium
azide (Costar, Cambridge, MA). The 48-well trays were stored at 4°C
until immunohistochemical processing.
Primary antibodies. The following primary antibodies were used:
affinity-purified rabbit polyclonal antibody 675 (Ab675) recognizing the
first 17 amino acids of wild-type and mutant huntingtin (kindly provided
by Dr. Jones, University of Wales, Cardiff, UK; Wilkinson et al., 1999);
the rabbit polyclonal EM48 antibody raised against the first 256 amino
acids of a huntingtin protein lacking the polyglutamine and polyproline
tracts (Li et al., 1999); a rabbit polyclonal anti-ubiquitin antibody (Dako);
a mouse monoclonal antibody recognizing the dopamine- and cAMP-
regulated phosphoprotein of 32 kDa (DARPP-32; a generous gift from
Drs. P. Greengard and H. C. Hemmings, Rockefeller University, New
York, NY); a rabbit polyclonal anti-DARPP-32 antibody (Chemicon,
Temecula, CA); and a mouse monoclonal antibody recognizing the
ChAT antibody (Roche Pharma).
Immunohistochemical procedure. The immunohistochemical procedure
was initiated by endogenous peroxidase quenching with a 30 min incu-
bation at 37°C in a PBS solution containing 0.1% diphenylhydrazine.
Free-floating sections were incubated at RT for 1 hr in 0.1 M PBS
containing 10% NGS (Dako), followed by a reaction with the respective
antibodies: EM48 (1:5000, 2 d RT), ubiquitin [1:1000; overnight (O/N)
4°C], mouse DARPP-32 (1:50,000, O/N 4°C), and ChAT (1:300, O/N
4°C), diluted in PBS and 5% NGS solution. After three washings, the
sections were incubated with the corresponding biotinylated secondary
antibody (1:200; Vector Laboratories) diluted in PBS and 1% NGS for 2
hr at RT, and bound antibody was visualized by using the Vectastain
ABC kit, with 3,3-diaminobenzidine tetrahydrochloride (DAB metal
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concentrate; Pierce) as substrate. The sections were mounted, dehy-
drated by passing twice through ethanol and toluol, and coverslipped
with Merckoglas. Triple stainings for DARPP-32, ChAT, and NADPH-d
or for huntingtin (EM48 Ab), ChAT, and NADPH-d were performed by
successive immunostainings with peroxidase substrates, DAB metal con-
centrate (brown), and 3-amino-9-ethylcarbazole (red peroxidase sub-
strate kit; Vector Laboratories) and enzymatic staining for NADPH-d
(blue). The nuclear localization of huntingtin was investigated on sec-
tions double-stained for huntingtin (EM48 Ab) and 4,6-diamidino-2-
phenylindole, dihydrochloride (DAPI). Huntingtin immunohistochemis-
try was done as previously described, and a tyramide substrate was used
for the detection (PerkinElmer Life Sciences). To avoid overstaining of
the nucleus, which could mask the dense nuclear aggregates, a short
development time was used. DAPI staining was performed as indicated
by the supplier (Molecular Probes Europe, Leiden, The Netherlands).
Degenerating neurons were stained with the anionic fluorescein deriva-
tive Fluoro-Jade B (Schmued and Hopkins, 2000). The sections were first
washed in water and then mounted on sylanized glass slides, dehydrated,
and stained according to the supplier’s manual (Schmued et al., 1997).
Finally, the enzymatic staining for NADPH-d was performed as previ-
ously described (Ellison et al., 1987).
Cell counting and evaluation of the volume of
DARPP-32-depleted region
The number of huntingtin aggregates, the DARPP-32-depleted volume,
and the estimation of ChAT and NADPH-d-immunoreactive neurons in
the DARPP-32-depleted region were determined with an automatic
image analysis system (SIS-Soft imaging system coupled to a ZX60
microscope, Olympus; Munster, Germany) on six sections separated by
400 m. The EM48-positive nuclei were counted at a magnification of
4, and the total number of aggregates per brain was obtained by
multiplying the counts by 16. The area of the striatum showing a loss of
DARPP-32 staining was measured for each animal with an operator-
independent macro. The volume was then estimated with the following
formula: volume d(a1 a2 a3 . . .), where d is distance between serial
sections (400 m), and a1, a2, a3 . . . are DARPP-32-depleted areas for
individual serial sections (Reynolds et al., 1998). Triple-stained sections
were used to determine the number of ChAT- and NADPH-d-positive
neurons in the DARPP-32-depleted area of htt171-82Q-injected animals.
The counts were performed at a magnification of 20, and the values
were expressed as percentages of neurons on the contralateral side.
Data analyses
Data are expressed as mean  SEM and were evaluated by ANOVA
followed by a Scheffe’s protected least significant difference post hoc test
(StatView 4.0, version 3.2.6; Aladdin Systems). The significance level was
set at p  0.05.
RESULTS
Lentiviral-mediated expression of truncated
human huntingtin
A Western blot analysis was performed to test the different
lentiviral vectors (Fig. 1A,B). Figure 1B shows that huntingtin
fragments with the predicted molecular weights are produced in
infected 293T cells and that there is no significant difference in
the expression levels. The capacity to overexpress human hun-
tingtin protein in a large area of the striatum of adult rats was
then assessed with the htt171-19Q and htt171-82Q vectors (Fig.
1C–E). One week after lentivirus injection, both wild-type and
mutant proteins were detected 1–2 mm from the injection site
(Fig. 1C,D). A gradual decrease in the intensity of the staining
was obtained as the distance from the injection site increased.
This gradient of expression probably reflects the progressive
decrease in transduction efficiency and as a consequence of the
number of integrated transgenes per cell, as indicated by in situ
hybridization experiments (data not shown). Sustained expres-
sion of the transgene was observed 3 months after injection of the
virus (Fig. 1E).
Injection of the htt171-82Q vector induces HD
neuropathology in the rat striatum
To analyze the progressive morphological changes associated
with the intrastriatal expression of htt171-82Q, rats were killed 1,
2, 4, 8, and 12 weeks after lentiviral injection. The formation of
huntingtin nuclear aggregates, a hallmark of the disease (Paulson,
2000), was used as a first marker to monitor the appearance of
pathology (Fig. 2A–E). None of the htt171-19Q-injected striata
were stained with the EM48 antibody (Fig. 2D). In contrast, the
expression of mutant htt171-82Q protein induced the formation
of huntingtin aggregates already detected 1 week after viral
injection (Fig. 2A). Although, huntingtin immunoreactivity is
generally detected in the whole nucleus, dense staining is present
in large spherical nuclear inclusions (NIs; Fig. 2K). Double stain-
ing with EM48 and DAPI confirmed that most of the aggregates
are present in the cell nucleus (Fig. 2L). The inclusions progres-
sively accumulate over the first 4 weeks, and their number re-
mains constant thereafter (Fig. 2B,C,E). In agreement with pre-
vious reports (Lin et al., 2001), we observed that these inclusions
are ubiquitinated as early as 2 weeks after lentivirus injection
(Fig. 2M,N). Interestingly, 8 and 12 weeks after injection, the
EM48 staining was no longer detectable in the immediate vicinity
of the injection site, suggesting that progressive striatal degener-
ation had occurred (Fig. 2C). New inclusions, however, appear at
Figure 1. A, Schematic representation of the lentiviral constructs used in
this study. cDNAs coding for the first 171, 853, and 1520 amino acids of
human huntingtin with 19, 44, 66, or 82 CAG repeats were cloned in the
SIN-W transfer vector. B, Western blot analysis, using the EM-48 anti-
body showing that huntingtin fragments of the expected molecular
weights are produced in human embryonic kidney 293T cells infected with
the corresponding lentiviral vectors. C–E, Photomicrographs of striatal
sections immunostained with the Ab675 antibody recognizing the
N-terminal part of huntingtin. One week after injection, both wild-type
(htt171-19Q; C) and mutant (htt171-82Q; D) huntingtin fragments are
overexpressed in a large area of the striatum. E, Sustained expression of
the transgene was observed 12 weeks after injection.
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the periphery of the lesion, resulting in an almost unchanged
overall inclusion number.
To further investigate whether the overexpression of htt171-
82Q is associated with neuronal dysfunction, striatal degenera-
tion, or both, an immunohistochemical analysis was performed
with the DARPP-32 antibody (Fig. 2F–J). This regulator of
dopamine receptor signaling (Greengard et al., 1999) is expressed
in 96% of the striatal medium-sized spiny neurons and is down-
Figure 2. Time course analysis of the neuropathology in htt171-19Q- and htt171-82Q-infected rats. A–C, Huntingtin aggregates were first detected 1
week after injection of htt171-82Q and progressively accumulated during the 12 week study period. D, As expected, huntingtin inclusions were not
identified with the EM48 antibody in the htt171-19Q-transduced hemisphere. E, Quantification of the number of cells containing huntingtin aggregates
in the striatum of htt171-82Q-injected rats. **p  0.01. F–H, Evaluation of the neurotoxicity of wild-type and mutant huntingtin fragments on
DARPP-32-stained striatal sections. G, Four weeks after infection, a drastic loss of DARPP-32-immunoreactive neurons was observed in the
htt171-82Q-infected striatum, whereas overexpression of the wild-type protein (htt171-19Q; I ) had no deleterious effect on DARPP-32 staining even at
3 months. J, Quantification of the DARPP-32-depleted region on the htt171-82Q-transduced striatal neurons. *p  0.05; **p  0.01; ***p  0.001. K,
EM48 staining showing an immunoreactive nucleus with neuronal intranuclear inclusions. L, DAPI and EM48 double staining showing that most of the
htt aggregates are located in the nucleus of htt171-82Q-infected neurons and colocalized with ubiquitin (M ). N, Ubiquitin staining in htt171-19Q-injected
rats.
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regulated in HD transgenic mice (Ouimet et al., 1998; Bibb et al.,
2000; Luthi-Carter et al., 2000; van Dellen et al., 2000). A loss of
DARPP-32 immunoreactivity in the striatum of htt171-82Q-
injected animals was observed at 4 weeks (Fig. 2G), a time point
that corresponds to the peak accumulation of NIs (152,700 
8140 NIs per animal). In animals injected with the htt171-82Q
lentivirus, a DARPP-32-depleted region of 1.14  0.23 mm3 was
measured, whereas no loss of DARPP-32 staining was detected
with the htt171-19Q fragment (Fig. 2 I,J). Similar results were
obtained with the neuronal marker NeuN (neuronal nuclei) (data
not shown). To assess whether the loss of DARPP-32 and NeuN
staining was attributable to neuronal dysfunction or cell death, we
first used the Fluoro-Jade B dye that stains preferentially degen-
erating neurons (Schmued et al., 1997; Schmued and Hopkins,
2000). Scattered fluorescent neurons as well as punctate staining
were visible 4–12 weeks after the injection of htt171-82Q (Fig.
3A). No staining was detected in htt171-19Q-transduced hemi-
spheres (Fig. 3B). Furthermore, an increased number of shrunken
hyperchromatic nuclei were observed over time on cresyl violet-
stained sections (Fig. 3C, arrowhead). Condensation of the inter-
nal capsule attributable to striatal tissue shrinkage was also
clearly visible on a bright-field image of the striatum at 12 weeks
(Fig. 3E). Finally, the expression of glial fibrillary acidic protein
(GFAP) was analyzed as an indicator of reactive astrogliosis
characteristic of HD. Twelve weeks after injection, robust GFAP
staining was observed around the injection site of htt171-82Q-
injected rats, whereas the GFAP staining was mild in htt171-91Q-
injected animals (Fig. 2G,H). Altogether these data indicate that
in Htt171-82Q-injected rats, the appearance of nuclear inclusions
precedes neuronal dysfunction and that the phenotype progresses
over 3 months, leading to a drastic degeneration of striatal neu-
rons associated with astrogliosis.
Specificity of toxicity in htt171-82Q-injected rats
HD is characterized by selective degeneration of GABAergic
neurons, with a relative sparing of ChAT and NADPH-d inter-
neurons, at least in the early stages of the disease (Vonsattel and
DiFiglia, 1998). Triple staining for DARPP-32, ChAT, and
NADPH-d was therefore performed to assess the specificity of
the pathology in htt171-82Q-injected rats (Fig. 4A,B). The num-
bers of ChAT- and NADPH-d-positive interneurons in the
DARPP-32-depleted area (DARPP-32-negative) were counted
and expressed as percentages of neurons on the contralateral side.
On average, 47.4  8.6% of ChAT-positive and 80.3  5.1% of
NADPH-d-positive neurons were preserved 3 months after injec-
tion (Fig. 4F). Double staining with EM48 and ChAT or
NADPH-d was performed to demonstrate that this was not the
result of resistance to lentiviral infection (Fig. 4C–E).
The neurodegenerative effect of htt171-82Q
is dose-dependent
The pathology obtained in this study is more severe than what has
been described in transgenic mice expressing the htt171-82Q
fragment (Schilling et al., 1999). This discrepancy is potentially
related to differences in transgene expression levels or species
specificity. To exclude the latter hypothesis, htt171-19Q and -82Q
lentiviruses were injected in the striatum of mice. Neuropathol-
ogy similar to what was described in rats was obtained (data not
shown). To test the dose-dependent hypothesis, the htt171-82Q
cDNA was cloned in an SIN-W transfer vector containing the
CMV promoter. We have previously demonstrated that this
promoter is weaker than the mouse PGK promoter in the stria-
tum of rats (de Almeida et al., 2001). As shown in Figure 5, the
DARPP-32-depleted area was smaller in CMV-htt171-injected
animals compared with the PGK-htt171-injected cohort. The
Figure 3. Progressive striatal degeneration in htt171-82Q-injected rats. A, The first indication of striatal degeneration was observed at 4 weeks on
Fluoro-Jade B-stained sections. C, At 8 weeks, pyknotic nuclei (arrowhead) were visible on cresyl violet-stained sections. E, Coalescence of the internal
capsule of the striatum was observed at 12 weeks on a bright-field photomicrograph. In contrast, no signs of degeneration were observed with the
wild-type huntingtin fragment (B, D, F, H ). Finally, robust GFAP staining was observed 3 months after injection in mutant htt (G) compared with
wild-type htt (H ).
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accumulation of htt aggregates was also delayed in CMV-htt171-
injected animals (1 week, 2331  714 PGK vs 2544  560 CMV;
2 weeks, 33,045  3661 vs 4027  1030; 4 weeks, 152,736  8140
vs 36,261 21,201; 8 weeks, 159,136 10,328 vs 16,293 12,210;
and 12 weeks, 163,200  16,819 vs 107,056  16,994). Unexpect-
edly, the htt aggregates were distributed in both the nucleus and
processes of CMV-htt171-injected animals (Fig. 6C,D), whereas
they were predominantly located in the nucleus of PGK-htt171-
injected rats (Fig. 6A,B).
The neuropathology correlates with CAG repeat length
In HD patients, a clear correlation between polyglutamine length
and disease severity has been reported (Duyao et al., 1993; Snell
et al., 1993; Furtado et al., 1996). This observation was assessed
with htt171 lentiviral constructs containing 19, 44, 66, and 82
CAG repeats. Aggregation of htt was evidenced 1 week after
injection of htt171-82Q vector, whereas the appearance of nuclear
inclusions was delayed by 1 and 3 weeks with the htt171-66Q and
htt171-44Q vectors, respectively (Fig. 7A). A direct correlation
between the polyglutamine length and the number of aggregates
was observed (Fig. 7B). A threshold effect was visible on DARPP-
32-stained sections, with an absence of pathology and huntingtin
fragments containing up to 44 CAG repeats (Fig. 8A). Moreover,
Figure 4. Specificity of the striatal toxicity in htt171-82Q-injected rats.
Low-power (A) and high-power (B) photomicrographs of a striatal sec-
tion triple-stained for DARPP-32 (red), ChAT (brown), and NADPH-d
(blue) show that 12 weeks after the injection of htt171-82Q, ChAT-
positive (arrowhead) and NADPH-d-positive (open triangle) interneurons
are still present at the center of the DARPP-32 depleted region. Double
staining shows that ChAT-positive (C, red) and NADPH-d-positive (E,
blue) neurons are transduced and develop large neuronal intranuclear
huntingtin aggregates (brown). D, Control, noninfected ChAT and
NADPH-d neurons. F, Quantification of the data illustrating the selective
sparing of ChAT and NADPH-d interneurons at 3 months.
Figure 5. Impact of huntingtin expression levels on the severity of the
pathology. The DARPP-32-depleted areas significantly decreased in
CMV-htt171-81Q-injected animals compared with PGK-htt171-82Q-
injected rats. *p  0.05; ***p  0.001.
Figure 6. Impact of huntingtin expression levels on the formation of
aggregates. We have previously shown that the CMV promoter leads to
a reduced expression level in the rat brain compared with the PGK
promoter. Decreasing the in vivo expression level of the Htt171-82Q
fragment alters the subcellular localization of the huntingtin inclusions
(A–D). Low-magnification (A) and high-magnification (B) photomicro-
graphs show that the EM48-immunoreactive aggregates in PGK-htt171-
82Q-injected animals are mainly restricted to the nucleus of infected
neurons, whereas both nuclear and neuritic aggregates are observed in the
CMV-htt171-82Q-injected animals (C, D).
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the size of the DARPP-32-depleted region in htt171-66Q-injected
animals was smaller compared with htt171-82Q rats (Fig. 8B).
Mutant htt toxicity is inversely correlated with htt
protein length
A series of vectors expressing truncated huntingtin proteins with
171, 853, and 1520 amino acids and either 19 or 82 CAG repeats
were produced to assess the impact of huntingtin protein length
on the development of the neuropathology. In the animals ex-
pressing htt853-82Q or htt1520-82Q, the number of nuclear in-
clusions was decreased, whereas the frequency of neuropil aggre-
gates was significantly augmented compared with htt171-82Q
(Figs. 9, 10). The appearance of a DARPP-32-depleted region
was also significantly delayed with the longer huntingtin frag-
ments (853 and 1520 amino acids; Fig. 10). At 3 months after
injection, a diffuse loss of DARPP-32 staining was observed with
the 853-amino acid construct. At 6 months after injection, the
DARPP-32-depleted region induced by the htt853-82Q injection
was comparable with the one obtained with the htt171-82Q con-
struct at 8 weeks. Finally, the longer htt1520-82Q construct had
Figure 7. Impact of polyglutamine repeat size on the formation of
huntingtin aggregates. A, Nuclear inclusions are first detected 4 weeks
after injection of the htt171-44Q lentiviral vector and progressively accu-
mulate over time. Increasing the CAG repeat size to 66 and 82 leads to an
earlier appearance of aggregates and a significant increase in the number
of nuclear inclusions. B, Quantification of the data showing the direct
relationship between CAG repeat size and aggregate formation. *p 
0.05; **p  0.01; ***p  0.001.
Figure 8. Influence of polyglutamine tract on the loss of DARPP-32
immunoreactivity. A, As expected, the overexpression of wild-type htt171
is not inducing a loss of DARPP-32 immunoreactivity. Interestingly, the
DARPP-32 staining is also preserved in the htt171-44Q-injected animals,
although huntingtin aggregates are first detected at 4 weeks in these
animals. In the htt171-66Q-injected animals, the first indication of cellular
dysfunction is observed at 4 weeks. Finally, a large DARPP-32-depleted
region was present around the injection site in the htt171-82Q group. B,
Quantification of the data showing the size of the DARPP-32-depleted
region. *p  0.05.
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only a minor effect on the DARPP-32 staining, even at 6 months
(Fig. 10).
DISCUSSION
In the present study, we demonstrated that lentiviral-mediated
delivery of mutant huntingtin provides a new strategy for devel-
oping animal models of HD. The local overexpression of htt
fragments with expanded polyglutamine repeats induced a cas-
cade of events with a progressive increase in the severity of the
phenotype consistent with the human pathology.
In the first set of experiments, we used htt-expressing lentiviral
vectors coding for the first 171 amino acids of the protein with 19
and 82 CAG repeats. Immunohistochemical analysis indicated
that transduced neurons overexpressing htt171 fragments are
present in a large area of the striatum. In htt171-82Q-injected
rats, intranuclear inclusions rapidly accumulate during the first 4
weeks. The EM48 staining, however, disappears from the center
of the transduced area 8 and 12 weeks after injection, whereas the
total number of NIs remains constant during that period. In situ
hybridization and immunohistochemical analysis with an anti-htt
antibody demonstrate that a gradient of expression is present in
lentiviral-injected animals. These observations suggest that a
striatal degeneration is occurring in these animals and that in-
fected neurons expressing high levels of mutant huntingtin are
first affected, whereas neurons located at the periphery of the
infected zone and expressing a lower level of htt develop aggre-
gates with slower kinetics. Decreasing the expression levels of
mutant htt (CMV-htt171-82Q) significantly delayed the kinetics
of appearance and the number of htt NIs and further supports
this interpretation. A dose effect was also described in an adeno-
associated virus-97Q-green fluorescent protein (GFP) study with
cells expressing high levels of 97Q-GFP being eliminated more
rapidly than cells expressing low levels of the mutant protein
(Senut et al., 2000). In agreement with previous reports in trans-
genic mice and presymptomatic patients, we observed that aggre-
gation occurs before ubiquitination (Mangiarini et al., 1996;
Gomez-Tortosa et al., 2001; Lin et al., 2001).
Decreasing the expression of mutant htt affects not only the
onset and severity of the pathology but also the subcellular
localization of htt aggregates. Intranuclear inclusions and neuritic
aggregates were observed in CMV-htt171-82Q-injected rats,
whereas the aggregates were mainly located in the nucleus of
PGK-htt171-82Q-infected cells. Previous studies have shown that
both nuclear and neuritic aggregates are present in several htt
transgenic mice (R6/2, N171-82Q, and Hdh80CAG; Li et al., 1999;
Schilling et al., 1999; Shelbourne et al., 1999). In R6/2 and
Hdh80CAG knock-in mice, the neuritic aggregates appear later
than the intranuclear inclusions (Li et al., 1999; Schilling et al.,
1999; Li et al., 2000). Finally, in HD patients, neuropil aggregates
are prevalent in cortical and striatal neurons (DiFiglia et al.,
1997). Our data raise the possibility that the formation of small
and abundant aggregates in axons and dendrites is favored in cells
expressing low levels of mutant huntingtin, whereas the develop-
ment of nuclear inclusions is associated with the presence of high
levels of htt.
The relative contribution of neuritic or nuclear aggregates or
both to the disease process is unclear, and whether they play a
role in the disease progression or, on the contrary, represent a
detoxifying mechanism to sequester abnormal proteins is still
debated (Sisodia, 1998). Recent in vitro findings suggest that the
presence of NIs can be dissociated from neuronal cell death
(Saudou et al., 1998; Evert et al., 1999; Kim et al., 1999). Dis-
crepancies between the topographic distribution of NIs and the
selective neuropathology of HD, spinocerebellar ataxia type 2
(SCA2), SCA7, and spinobulbar muscular atrophy have also been
reported (Holmberg et al., 1998; Li et al., 1998; Koyano et al.,
1999; Kuemmerle et al., 1999). Finally, no significant neuronal
degeneration was observed in several HD transgenic mice with
Figure 9. Impact of huntingtin protein length on the formation of ag-
gregates. Increasing the huntingtin fragment size from 171 to 853 and
1520 amino acids significantly delays the appearance of neuronal aggre-
gates. *p  0.05; **p  0.01; ***p  0.001.
Figure 10. Striatal neuropathology 6 months after injection of lentiviral
vectors coding for huntingtin fragments of various lengths. A, In htt171-
82Q-injected rats, EM48-positive nuclear inclusions are still present but
are mainly located at the limit of the degenerating area, whereas aggre-
gates are detected around the injection site with the longer huntingtin
fragments (C, E). Note that increasing the huntingtin fragment size
modifies the subcellular localization of aggregates from nuclear to neu-
ritic (A, C, E). B, D, F, The onset of the pathology, based on DARPP-32
immunoreactivity, is also significantly delayed with longer huntingtin
fragments. A moderate loss of DARPP-32 staining is seen with the htt853
vector, whereas limited neuropathology, with DARPP-32 staining still
present in neuronal cell bodies is observed in htt1520-82Q-injected rats.
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numerous NIs, whereas others show mild striatal neurodegenera-
tion with relatively few NIs (Mangiarini et al., 1996; Reddy et al.,
1998; Hodgson et al., 1999; Schilling et al., 1999). Taken together,
these data indicate that aggregation is a good indicator for the
presence of abnormal conformation of htt and thus may be an
indirect marker for a pathogenic process, but that these inclusions
are not themselves necessarily causes of cell death.
Accumulating evidence suggests that neuronal dysfunction pre-
cedes striatal degeneration in HD. Magnetic resonance imaging,
computed tomographic, and positron emission tomographic stud-
ies indicate that neuronal alterations are present before the ap-
pearance of clinical symptoms (Mazziotta et al., 1987; Grafton et
al., 1990; Aylward et al., 1994, 2000; Antonini et al., 1996; An-
drews et al., 1999). A decrease in DARPP-32 expression was, for
example, observed in early symptomatic transgenic mice showing
no obvious cell loss (Bibb et al., 2000; Luthi-Carter et al., 2000;
Menalled et al., 2000; van Dellen et al., 2000). We have therefore
used a DARPP-32 antibody to monitor the appearance of neuro-
nal dysfunction in htt171-82Q-injected rats. In all cases, the loss
of DARPP-32 immunoreactivity was delayed compared with the
occurrence of nuclear inclusions. Beginning 4 weeks after injec-
tion, a DARPP-32-depleted region was observed around the
injection site in the htt171-82Q-injected rats. At 1 month after
injection, Fluoro-Jade B staining suggested that a neurodegen-
erative process accompanied the downregulation of DARPP-32
staining. At later time points, cresyl violet staining and the pro-
gressive shrinkage of the tissue clearly demonstrated that robust
cell death occurred in htt171-82Q-injected rats.
Importantly, this degenerative process is not affecting all neu-
ronal subpopulations. In agreement with the human disease, a
selective sparing of ChAT and NADPH-d neurons was observed
despite the presence of NIs in both neuronal populations (Ellison
et al., 1987; Ferrante et al., 1987). Further studies are needed to
determine whether all infected ChAT and NADPH-d neurons
develop NIs or whether the frequency of aggregate formation is
lower in these interneurons, as suggested by Kosinski et al.
(1999). Our results also indicate that the expression of mutant htt
in the striatum is sufficient to induce a neuropathology and a
specific degeneration of GABAergic neurons. Lentiviral-
mediated delivery of mutant htt in the cortex should provide
further information on the potential contribution of glutamater-
gic neurons in HD pathology.
In a second set of experiments, we showed that the onset of
pathology is inversely correlated with the number of CAG repeats
similarly to what has been observed in HD patients (Andrew et
al., 1993; Craufurd and Dodge, 1993; Persichetti et al., 1995;
Becher et al., 1998). At 3 months, no loss of DARPP-32 staining
was observed with the htt171-44Q vector despite the presence of
NIs in some of the infected neurons. This might be attributable to
the limited time frame of analysis and the incomplete penetrance
of the disease with short CAG expansion. In contrast, rats in-
jected with the htt171-66Q vector showed the typical loss of
DARPP-32 staining and a progressive accumulation of htt aggre-
gates. As expected, the phenotype was milder than in htt171-82Q-
injected animals.
Finally, a temporal and spatial analysis of the striatum revealed
that the pathogenesis is modulated by htt protein length. The
number of aggregates was significantly decreased in htt853-82Q-
and htt1520-82Q-injected rats compared with htt171-82Q-
injected animals. This result is in agreement with previous in vitro
studies (Lunkes and Mandel, 1998; Saudou et al., 1998; Karpuj et
al., 1999). Moreover, the frequency of neuritic aggregates was
increased with the longer htt fragments. The phenomenon has
also been observed in cells infected with amplicon vectors coding
for various htt fragments (Martindale et al., 1998). The observa-
tion that the pathology is inversely proportional to the huntingtin
protein size is consistent with the late onset phenotype observed
in htt full-length YAC72 mice (Hodgson et al., 1999) and the
early onset pathology of R6/2 htt exon 1 mice (Davies et al.,
1997). Recent studies suggest that the full-length huntingtin
protein may diminish the overall toxicity of polyglutamine re-
peats and may contain antiapoptotic domains (Rigamonti et al.,
2000).
Although it was not our primary objective, we investigated
whether the expression of mutant huntingtin in the rats caused
apomorphine-induced rotation. None, however, showed behav-
ioral impairments, suggesting that only multiple injections may
lead to behavioral abnormalities.
In summary, these results demonstrate that lentiviral-mediated
delivery of htt171-82Q but not htt171-19Q induces a pathology
characterized by rapid appearance of neuritic or nuclear ubiqui-
tinated huntingtin aggregates, or both, followed by neuronal
dysfunction and astrogliosis, leading finally to robust and selec-
tive degeneration of striatal GABAergic neurons. In addition, a
correlation was observed among polyglutamine repeat size, hun-
tingtin protein length, expression levels and the onset and severity
of the pathology (Fig. 11). Lentiviral-mediated injection of mu-
tant htt may therefore provide a flexible setting to dissect the
molecular mechanisms leading to the specific degeneration of
medium spiny striatal neurons in vivo and to evaluate potential
therapeutic molecules that may prevent or delay the onset of the
disease.
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